Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Emtansine vs Trastuzumab + Docetaxel in HER2+ Metastatic Breast Cancer
NCT02144012Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2014
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of trastuzumab emtansine in breast cancer, sponsored by Roche. Started Jun 2014; status: terminated.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02144012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144012.